Myomo Announces CFO Succession

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Myomo Inc. (NYSE American MYO) (“Myomo,” or the “Company”), a wearable
medical robotics company that offers expanded mobility for those
suffering from neurological disorders and upper limb paralysis, today
announced that Ralph A. Goldwasser, its Chief Financial Officer, is
retiring effective as of February 18, 2019. Mr. Goldwasser, age 71, will
provide transitional services to the Company for an expected three-month
term under a transition and consulting agreement.

He will be succeeded by David Henry, effective February 18, 2019. Mr.
Henry, age 57 has more than thirty years of experience in
high-technology manufacturing companies, including more than a dozen
years as Chief Financial Officer of publicly traded companies. Mr. Henry
is joining Myomo from Eos Energy Storage, a privately held manufacturer
of grid-scale energy storage systems for utilities and renewable project
developers, where he has served as Chief Financial Officer since August
2017. Prior to Eos, Mr. Henry served as Chief Financial Officer of
American Superconductor Corporation (NASDAQ: AMSC) from July 2007 to
June 2017 and as Chief Financial Officer of AMI Semiconductor (NASDAQ:
AMIS), from April 2004 to July 2007. He has also held various financial
executive roles at Fairchild Semiconductor and National Semiconductor.

Paul R. Gudonis, Chairman and CEO of Myomo, said, “I would like to thank
Ralph, who has worked with me at Myomo for the past eight years, first
as a consulting CFO and later as our Chief Financial Officer, enabling
us to raise growth capital, including leading our June 2017 IPO and
listing on the NYSE American exchange and our follow-on equity financing
in December of 2017. We wish Ralph the best in his retirement. We are
pleased to have David Henry join Myomo’s executive team as Chief
Financial Officer. David has extensive experience to support our efforts
to grow the Company.”

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers expanded
mobility for those suffering from neurological disorders and upper limb
paralysis. Myomo develops and markets the MyoPro product line. MyoPro is
a powered upper limb orthosis designed to support the arm and restore
function to the weakened or paralyzed arms of patients suffering from
CVA stroke, brachial plexus injury, traumatic brain or spinal cord
injury, ALS or other neuromuscular disease or injury. It is currently
the only marketed device that, sensing a patient’s own EMG signals
through non-invasive sensors on the arm, can restore an individual’s
ability to perform activities of daily living, including feeding
themselves, carrying objects and doing household tasks. Many are able to
return to work, live independently and reduce their cost of care. Myomo
is headquartered in Cambridge, Massachusetts, with sales and clinical
professionals across the U.S. and a business development office in
Europe. For more information, please visit

Forward Looking Statements

This press release contains forward-looking statements regarding the
Company’s future business expectations which are subject to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements include, but are not limited to,
statements about the expansion of our business and commercial
operations, David Henry’s joining our company as Chief Financial Officer
and Mr. Goldwasser’s service to us in a transitional role. These
forward-looking statements are only predictions and may differ
materially from actual results due to a variety of factors. Our actual
results could differ materially from those anticipated in these forward
looking statements for many reasons, including, without limitation,
risks related to regulatory approval and market acceptance of our
products, our ability to secure and maintain reimbursement for our
products, our ability to obtain additional funding to sustain and grow
our business, and the other risk factors contained in our filings made
with the Securities and Exchange Commission. More information about
factors that potentially could affect Myomo’s financial results is
included in Myomo’s filings with the Securities and Exchange Commission.
The Company cautions readers not to place undue reliance on any such
forward-looking statements, which speak only as of the date made. The
Company disclaims any obligation subsequently to revise any
forward-looking statements to reflect events or circumstances after the
date of such statements or to reflect the occurrence of anticipated or
unanticipated events.


Contacts For Myomo:

Investor Relations:
PCG Advisory
Vivian Cervantes


Public Relations:
Matter Communications
Meredith Krim

error: Content is protected !!